In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.
Subscribe to:
Post Comments (Atom)
< + > Making AI and NLP Affordable and Trusted in Health Care
emtelligent offers a variety of AI-based services in health care. In a recent interview at the HLTH conference with Tim O’Connell, MD, Co-F...
-
As I’m sure you know, times are tough. Wages have largely remained the same while prices have risen across the board – and healthcare is no ...
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
No comments:
Post a Comment